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j ourna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/ i jc -hear t -and-vascu la tureQRS duration predicts 30 day mortality
following ST elevation myocardial infarctionThe study population was divided into two groups; QRS b 100 msTable 1
Multivariate predictors for QRS ≥100 ms and 30 day or 1 year all-cause mortality.
HR (95% CI) P value
30 day mortality
QRS duration on admission 2.29 (1.23–4.29) b0.01
Age 1.04 (1.02–1.07) b0.01
Percutaneous coronary intervention 0.44 (0.24–0.81) b0.01
Tachycardia 2.64 (1.39–5.04) b0.00
1 year mortality
QRS duration on admission 2.28 (1.38–3.76) b0.01
Age 1.03 (1.01–1.05) b0.01
Hypertension 2.39 (1.14–5.02) 0.02
Percutaneous coronary intervention 0.43 (0.26–0.69) b0.01
Tachycardia 1.90 (1.11–3.25) 0.00
Hypotension 2.77 (1.43–5.36) b0.01Keywords:
QRS duration
Ventricular arrhythmias
30 day mortality
ST elevation myocardial infarction
Studies have demonstrated an association between QRS duration
and long term mortality after myocardial infarction [1,2].
However, there remains a scarcity of data on QRS duration after ST
elevation myocardial infarction (STEMI) and its association with mor-
tality.We investigatedwhether QRS duration during STEMI hospitaliza-
tion could predict 30-day and one yearmortality. A secondary objective
was to determine the relationship between prolonged QRS and occur-
rence of inpatient ventricular arrhythmias.
Five hundred and ﬁfty three patients admitted to Einstein Medical
Center, Philadelphia from August 1, 2006 to August 31, 2011 with a
diagnosis of STEMI were screened. The study protocol was approved
by our Institutional Review Board. The author(s) of this manuscript
have certiﬁed that they comply with the principles of ethical publishing
in the International Journal of Cardiology.
STEMI was diagnosed on the basis of cardiac symptoms and electro-
cardiographic changes consisting of ST elevation in two contiguous
leads in accordance with the guidelines [3].
Patients with any of the following were excluded:
1) Known prior QRS duration ≥100 ms
2) Bundle branch block
3) Paced rhythm on admission
4) Patients with incomplete data set.
All EKGs from the time of presentation to the time of discharge/
death of the patient, as well as telemetry data, were reviewed to deter-
mine the QRS duration on admission and the development of inpatient
ventricular arrhythmias (ventricular tachycardia (VT) and ventricular
ﬁbrillation (VF)) during that hospital stay.
QRS durations from ﬁfty random EKGs were measured by both
manual and electronic means and then compared to ascertain accuracy
and reliability of the electronic method of collection whichwas eventu-
ally used for EKG measurements (R2 = 0.96, P b 0.0001).
Data on patient demographics and clinical characteristics, baseline
hemodynamic parameters, ejection fraction, obtained from transthoracic
echocardiogram reports, and type of intervention done (percutaneous
coronary intervention (PCI) or coronary artery bypass graft (CABG))
were collected.
Mortality at 30 days and one year was determined from hospital
records and the publically accessed social security death index
website.http://dx.doi.org/10.1016/j.ijcha.2014.10.010
2352-9067/© 2014 Published by Elsevier Ireland Ltd. This is an open access article under the Cand QRS ≥ 100 ms. The cut-off of 100 ms was used because it yielded
the highest accuracy on analysis. Baseline characteristics of each group
were compared using independent-sample t tests for continuous
variables and chi-square or Fisher's exact test for discrete variables.
Multivariate Cox proportional hazards regression models were used to
evaluate independent predictors of mortality. Kaplan–Meier method
was used for generating survival curves and compared using the log-
rank test. The effect of each variable was expressed as an odds ratio
(OR) and conﬁdence interval (CI). A p value b 0.05 was considered sta-
tistically signiﬁcant. Statistical analyses were performed using SPSS,
version 22.
The ﬁnal cohort consisted of 449 patients with mean age of 61 ± 14
years, 41% were female and the average QRS duration was 96 ± 23 ms.
During hospitalization, 13.3% of patients with QRS ≥ 100 ms on ad-
mission had an episode of VT compared to 4.9% of those with a
QRS b 100 ms (p = 0.01). Likewise those with a QRS ≥ 100 ms had
slightly more episodes of VF compared to those with a QRS b 100 ms
though it was not statistically signiﬁcant (17.1% and 16.0% respectively;
p = 0.760).
Multivariate analysis revealed that patients with a QRS duration
≥100 ms had increased 30-day mortality (HR = 2.30, 95% CI 1.2–4.3;
p b 0.01) and 1 year mortality (HR = 2.28, 95% CI 1.4–3.8; p b 0.01)
(Table 1) compared to patients with QRS duration b100 ms (TIMI
score variables, ejection fraction, chronic kidney disease, hypotension
and tachycardia on presentation were adjusted). They also had an in-
creased occurrence of VT (OR = 3.49, 95% CI 1.6–7.5; p b 0.01) but not
VF (OR = 1.01, 95% CI 0.5–1.9; p = 0.97). Kaplan–Meier curve
stratiﬁed by QRS duration ≥100 ms versus QRS duration b100 ms
showed that there was an increase in 30 day and one year mortality in
patients that had prolonged QRS duration (Fig. 1).
The QRS duration which has recently found its place in determin-
ing those patients with heart failure that might beneﬁt from cardiacC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Kaplan–Meier survival estimates of 30 day mortality and 1 year mortality.
43QRS duration predicts 30 day mortality following ST elevation myocardial infarctionresynchronization therapy [4], has been underutilized in the prog-
nostication of patients that might do poorly post-MI.
There has been controversy over whether QRS duration alone can
predict the development of arrhythmias post-infarction. One study con-
cluded that QRS duration cannot be used as a standalone predictor of ar-
rhythmias post-infarction, however most patients in this study had MI
that occurred more than six months prior to the time of enrollment
into the study [5]. On literature review there was no study found that
speciﬁcally addressed the relationship between QRS prolongation at
the time of MI hospitalization and short term mortality or in-patient
ventricular arrhythmias after STEMI.
In this study, multivariate analysis demonstrated that patients
with QRS duration ≥100 ms admitted with STEMI have a 2.3 fold in-
crease in 30 day mortality compared to those with a QRS duration
b100 ms.
Several studies have hypothesized that post-MI QRS prolongation
might be due to scar tissue formation affecting the conduction system,
which could predispose to reentry and ultimately dangerous ventricular
arrhythmias [6–8]. Another study hypothesized that the association of
QRS prolongation post-STEMI and increased long-term mortality
might be due to late potentials that are large enough to affect the surface
EKG, suggesting extensive infarcts and involvement of the interventric-
ular conduction system [9]. The ability of the QRS duration to predict
30 daymortality, found in the present study,may be useful in stratifying
patients into a group that requires more aggressive care; for example,
being discharged with a life vest to protect against ventricular arrhyth-
mias post-STEMI and hence sudden death, versus those that may only
require routine monitoring.
The limitations we had included difﬁculty to determine cause of
death after a patient leaves the hospital hence 30 day mortality was
all cause mortality which is less reliable in demonstrating a direct
cause and effect relationship. STEMI patients were placed on guideline
directed therapy that may have affected the QRS duration. Finally, our
subject populationwas predominantly blackwhichmight limit general-
izing our results to other populations.
QRS duration ≥100 ms is an independent predictor of 30-day and
one year mortality and in-patient ventricular tachycardia after STEMI.
QRS duration should be considered in further STEMI risk stratiﬁcation
and aggressive arrhythmia management.
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